The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 12, 2013
Filed:
Jul. 03, 2007
Jung Joon Lee, Taejeon-si, KR;
Jeong-hyung Lee, Taejeon-si, KR;
Kyeong Lee, Taejeon-si, KR;
Young-soo Hong, Taejeon-si, KR;
B. K. Shanthaveerappa, Taejeon-si, KR;
Yinlan Jin, Taejeon-si, KR;
Jin Hwan Kim, Taejeon-si, KR;
Xuejun Jin, Taejeon-si, KR;
Jung Joon Lee, Taejeon-si, KR;
Jeong-Hyung Lee, Taejeon-si, KR;
Kyeong Lee, Taejeon-si, KR;
Young-Soo Hong, Taejeon-si, KR;
B. K. Shanthaveerappa, Taejeon-si, KR;
Yinlan Jin, Taejeon-si, KR;
Jin Hwan Kim, Taejeon-si, KR;
Xuejun Jin, Taejeon-si, KR;
Korea Research Institute of Bioscience and Biotechnology, Daejeon, KR;
Abstract
Disclosed herein are an HIF-1 inhibitor, a method for the preparation thereof, and a pharmaceutical composition comprising the same as an active ingredient. The HIF-1 inhibitor shows anticancer activity thanks to the inhibition activity against HIF-1, a transcription factor which plays an important role in the growth and metastasis of cancer, but not to general cytotoxicity. Thus, the HIF-inhibitor and a pharmaceutically acceptable salt thereof can be used as a therapeutic for various cancers such as liver cancer; stomach cancer and breast cancer. Also, the compound having inhibition activity against HIF-1 is useful in the treatment of diabetic retinopathy and arthritis, which are aggravated by HIF-1-mediated VEGF expression.